The present invention relates to phosphodiesterase (PDE) type 4, phosphodiesterase (PDE) type 7 and dual PDE type 4 /PDE type 7 inhibitors. Compounds disclosed herein can be useful in the treatment, prevention, inhibition or suppression of CNS diseases, for example, multiple sclerosis various pathological conditions such as diseases affecting the immune system, including AIDS, rejection of transplant, auto-immune disorders such as T-cell related diseases, for example, rheumatoid arthritis inflammatory diseases such as respiratory inflammation diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchitis, allergic rhinitis, adult respiratory distress syndrome (ARDS) and other inflammatory diseases including but not limited to psoriasis, shock, atopic dermatitis, eosinophilic granuloma, allergic conjunctivitis, osteoarthritis gastrointestinal inflammation diseases such as Crohns disease, colitis, pancreatitis as well as different types of cancers including leukaemia especially in humans. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type 4, PDE type 7 and dual PDE type 4 /PDE type 7 inhibitors are provided.La présente invention concerne des inhibiteurs de la phosphodiestérase (PDE) de type 4, de la phosphodiestérase (PDE) de type 7, et un double inhibiteur de PDE de type 4 / PDE de type 7. Les composés de linvention conviennent au traitement, à la prévention, à linhibition ou à la suppression de maladies du système nerveux central telles que la sclérose en plaques de divers états pathologiques affectant le système immunitaire et notamment le SIDA, le rejet de greffe, les maladies auto-immunes telles que les maladies relatives aux lymphocytes T comme par exemple la polyarthrite rhumatoïde de maladies inflammatoires telles que les maladies inflammatoires respiratoires et notamment la broncho-pneumopathie chronique obstructive, lasthme, la bronchite, la rhini
